S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:GMDA

Gamida Cell Competitors

$8.43
-0.53 (-5.92 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.03
Now: $8.43
$9.21
50-Day Range
$7.83
MA: $9.75
$12.43
52-Week Range
$2.60
Now: $8.43
$15.00
Volume904,550 shs
Average Volume1.28 million shs
Market Capitalization$204.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03

Competitors

Gamida Cell (NASDAQ:GMDA) Vs. TCRR, STRO, ADAP, VXRT, ORTX, and ATHA

Should you be buying GMDA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Gamida Cell, including TCR2 Therapeutics (TCRR), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Vaxart (VXRT), Orchard Therapeutics (ORTX), and Athira Pharma (ATHA).

TCR2 Therapeutics (NASDAQ:TCRR) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

82.1% of TCR2 Therapeutics shares are held by institutional investors. 28.0% of TCR2 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

TCR2 Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares TCR2 Therapeutics and Gamida Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TCR2 TherapeuticsN/A-35.51%-34.02%
Gamida CellN/A-112.47%-65.09%

Analyst Ratings

This is a breakdown of current ratings and price targets for TCR2 Therapeutics and Gamida Cell, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TCR2 Therapeutics00703.00
Gamida Cell00503.00

TCR2 Therapeutics currently has a consensus target price of $39.2857, indicating a potential upside of 63.28%. Gamida Cell has a consensus target price of $18.50, indicating a potential upside of 119.45%. Given Gamida Cell's higher probable upside, analysts plainly believe Gamida Cell is more favorable than TCR2 Therapeutics.

Earnings & Valuation

This table compares TCR2 Therapeutics and Gamida Cell's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.99

TCR2 Therapeutics is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.

Summary

TCR2 Therapeutics beats Gamida Cell on 6 of the 10 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

78.8% of Sutro Biopharma shares are held by institutional investors. 28.9% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Sutro Biopharma has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares Sutro Biopharma and Gamida Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
Gamida CellN/A-112.47%-65.09%

Analyst Ratings

This is a breakdown of current ratings and price targets for Sutro Biopharma and Gamida Cell, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
Gamida Cell00503.00

Sutro Biopharma currently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. Gamida Cell has a consensus target price of $18.50, indicating a potential upside of 119.45%. Given Gamida Cell's stronger consensus rating and higher probable upside, analysts plainly believe Gamida Cell is more favorable than Sutro Biopharma.

Earnings & Valuation

This table compares Sutro Biopharma and Gamida Cell's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.99

Gamida Cell has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.

Summary

Sutro Biopharma beats Gamida Cell on 7 of the 13 factors compared between the two stocks.

Adaptimmune Therapeutics (NASDAQ:ADAP) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

99.8% of Adaptimmune Therapeutics shares are held by institutional investors. 18.9% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Adaptimmune Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares Adaptimmune Therapeutics and Gamida Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptimmune Therapeutics-3,858.14%-44.94%-33.70%
Gamida CellN/A-112.47%-65.09%

Analyst Ratings

This is a breakdown of current ratings and price targets for Adaptimmune Therapeutics and Gamida Cell, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptimmune Therapeutics03202.40
Gamida Cell00503.00

Adaptimmune Therapeutics currently has a consensus target price of $15.50, indicating a potential upside of 209.38%. Gamida Cell has a consensus target price of $18.50, indicating a potential upside of 119.45%. Given Adaptimmune Therapeutics' higher probable upside, research analysts plainly believe Adaptimmune Therapeutics is more favorable than Gamida Cell.

Earnings & Valuation

This table compares Adaptimmune Therapeutics and Gamida Cell's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptimmune Therapeutics$1.12 million692.36$-137,160,000.00($1.32)-3.80
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.99

Gamida Cell has lower revenue, but higher earnings than Adaptimmune Therapeutics. Gamida Cell is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Adaptimmune Therapeutics beats Gamida Cell on 9 of the 13 factors compared between the two stocks.

Vaxart (NASDAQ:VXRT) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Profitability

This table compares Vaxart and Gamida Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vaxart-281.50%-84.90%-44.67%
Gamida CellN/A-112.47%-65.09%

Insider & Institutional Ownership

17.9% of Vaxart shares are held by institutional investors. 7.3% of Vaxart shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Vaxart has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Vaxart and Gamida Cell, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxart00203.00
Gamida Cell00503.00

Vaxart currently has a consensus target price of $15.00, indicating a potential upside of 153.38%. Gamida Cell has a consensus target price of $18.50, indicating a potential upside of 119.45%. Given Vaxart's higher probable upside, research analysts plainly believe Vaxart is more favorable than Gamida Cell.

Earnings & Valuation

This table compares Vaxart and Gamida Cell's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaxart$9.86 million70.71$-18,650,000.00($0.86)-6.88
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.99

Vaxart has higher revenue and earnings than Gamida Cell. Vaxart is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.

Summary

Vaxart beats Gamida Cell on 8 of the 12 factors compared between the two stocks.

Gamida Cell (NASDAQ:GMDA) and Orchard Therapeutics (NASDAQ:ORTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Gamida Cell and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gamida CellN/A-112.47%-65.09%
Orchard TherapeuticsN/A-65.65%-47.92%

Insider & Institutional Ownership

66.6% of Orchard Therapeutics shares are held by institutional investors. 4.2% of Orchard Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Gamida Cell has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Orchard Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Gamida Cell and Orchard Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gamida Cell00503.00
Orchard Therapeutics00403.00

Gamida Cell currently has a consensus price target of $18.50, indicating a potential upside of 119.45%. Orchard Therapeutics has a consensus price target of $14.75, indicating a potential upside of 115.01%. Given Gamida Cell's higher probable upside, equities analysts plainly believe Gamida Cell is more favorable than Orchard Therapeutics.

Valuation and Earnings

This table compares Gamida Cell and Orchard Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.99
Orchard Therapeutics$2.51 million265.83$-163,420,000.00($1.75)-3.92

Gamida Cell has higher earnings, but lower revenue than Orchard Therapeutics. Gamida Cell is trading at a lower price-to-earnings ratio than Orchard Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Orchard Therapeutics beats Gamida Cell on 6 of the 11 factors compared between the two stocks.

Gamida Cell (NASDAQ:GMDA) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Gamida Cell and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gamida CellN/A-112.47%-65.09%
Athira PharmaN/AN/AN/A

Insider & Institutional Ownership

66.7% of Athira Pharma shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Gamida Cell and Athira Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gamida Cell00503.00
Athira Pharma00403.00

Gamida Cell currently has a consensus price target of $18.50, indicating a potential upside of 119.45%. Athira Pharma has a consensus price target of $42.50, indicating a potential upside of 120.32%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Gamida Cell.

Valuation and Earnings

This table compares Gamida Cell and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.99
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Summary

Athira Pharma beats Gamida Cell on 5 of the 6 factors compared between the two stocks.


Gamida Cell Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.7%$210.11 million$104.39 million-3.40
Axcella Health logo
AXLA
Axcella Health
1.6$5.51-3.1%$206.85 millionN/A-2.56
INmune Bio logo
INMB
INmune Bio
1.5$15.37-22.5%$206.70 millionN/A-15.85Earnings Announcement
News Coverage
Genfit logo
GNFT
Genfit
1.3$4.87-2.7%$189.24 million$45.88 million-2.47
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.18-6.7%$186.70 millionN/A-8.76Gap Up
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$4.23-14.2%$178.75 million$1.45 million-1.48Earnings Announcement
Analyst Upgrade
Increase in Short Interest
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$8.90-0.7%$178.60 millionN/A-2.27Gap Up
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$5.35-4.3%$168.68 million$20,000.000.00Decrease in Short Interest
Gap Down
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.5$13.01-19.3%$166.26 million$2.33 million0.00Upcoming Earnings
Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.1$11.70-0.9%$156.42 million$32.12 million-90.00Upcoming Earnings
News Coverage
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.